Cadila gets DGCI nod for Phase II clinical trials of ZYH1

New Delhi, Mar 20 (UNI) Cadila Healthcare Ltd today said it has received permission from Drug Controller General of India to conduct Phase II clinical trials on its new molecular entity ZYH1, after successfully completing Phase I clinical trials.

The Phase II studies would focus on evaluating the efficacy of ZYH1.

ZYH1 is expected to address the issue related to patients suffering from dyslipidemia in both diabetic and non-diabetic condition.

The drug, designed and developed by the company's research wing, Zydus Research Centre, is expected to improve lipid profile, leading to decrease in cardiovascular risk in diabetic patients as well as other diabetes-related complications.

UNI SR SD KN1743